Preliminary findings of altered follicular activity in Holstein cows with coagulation factor XI deficiency

1995 ◽  
Vol 19 (6) ◽  
pp. 463-471 ◽  
Author(s):  
R. M. Liptrap ◽  
P. A. Gentry ◽  
M. L. Ross ◽  
E. Cummings
2015 ◽  
Vol 6 (3) ◽  
pp. 69-73
Author(s):  
Yessengali Serikovich Ussenbekov ◽  
Orik Orazimanovna Zhanserkenova ◽  
Shinar Nikolaevna Kasymbekova ◽  
Sarsenbek Torekhanovich Siyabekov ◽  
Ivan Viktorovich Sobolev ◽  
...  

Minor bleeding is quite common in children and in some cases masks the serious disease of blood clotting. As a rule, this rare inherited disease associated with deficiency of coagulation factors as the I, II, V, VII, X, XI and XIII, as well as deficiency conjugate, most often, the joint failure factors V and VIII and factor whose synthesis associated with vitamin K. The pediatric clinic is difficult to fulfill a randomized trial because of the difficulty of identifying such children carriers of genetic abnormalities at a specific blood clotting factor. In connection with the model of deficiency of coagulation factor XI in a mammals (Bos Taurus L) with autosomal recessive type of inheritance is particularly promising. Deficiency of coagulation factor XI in cattle is inherited autosomal recessive defect. At the first time this pathology was recognized in Holstein cows in 1969. Frequently the etiologic factor of most hidden genetic defects in animals are point mutations in the coding region of the respective genes. On the contrary it has been found that deficiency of coagulation factor XI cattle (FXID) is a consequence of the insertion of nucleotide sequences within exon 12 of the gene FXI length of 76 base pairs. STOP codon (TAA) was resulted from insertion. Phenotypically deficiency of factor XI (FXID) in calves is resulted in disturbance of blood clotting and characterized by prolonged bleeding from the umbilical cord and anemia. Cows which are heterozygous in deficiency of coagulation factor XI have colostrum pink color. Those animals are frequently suffered from pneumonia, mastitis and endometritis. We monitored the breeding sires and Holstein cows on the carrier of the genetic disease: deficiency of coagulation factor XI. To detect the insertion of nucleotide sequences of 76 bp in size it is recommended to use the polymerase chain reaction.


Haemophilia ◽  
2017 ◽  
Vol 24 (2) ◽  
pp. e50-e55 ◽  
Author(s):  
V. Rimoldi ◽  
E. M. Paraboschi ◽  
M. Menegatti ◽  
F. Peyvandi ◽  
O. Salomon ◽  
...  

2012 ◽  
Vol 52 (11) ◽  
pp. 1042 ◽  
Author(s):  
B. Akyuz ◽  
S. Sariozkan ◽  
D. Bayram

The aim of this study was to compare the prevalence of factor XI deficiency (FXID) carriers and potential financial losses depending on ‘extended calving interval’ and ‘extra service’ in normally fertile and repeat breeder cows in Turkey. For this purpose, a total of 161 Holstein cows were genotyped for the FXI gene mutation originating from various herds located in the Middle Anatolian region of Turkey. In the study, animals were divided into two groups – normally fertile (n = 118) and repeat breeding (n = 43) cows. In each group, one FXID carrier animal was identified and the prevalence of the FXID carrier was found to be 0.85 and 2.33% in normally fertile and repeat breeder cows, respectively. In a financial analysis, it was determined that extended calving interval in a normally fertile cow caused $246 losses and $546 losses in a repeat breeder cow. Additionally, financial losses due to extra service per conception were calculated as $12 and $36 per cow in normally fertile and repeat breeder cows, respectively. In normally fertile and repeat breeder cows, the sum of losses due to extended calving interval and extra service was calculated as $258 (246 + 12) and $582 (546 + 36). This study found that a repeat breeder cow causes an extra $324 ($582 – $258) financial loss compared with a normally fertile cow. Consequently, unlike other genetic disorders like BLAD and DUMPS, which do not decrease the performance of carrier animals, the mutant FXI allele could lead to repeat breeder syndrome in FXID carrier cows and cause important financial losses in dairy farms.


1999 ◽  
Vol 82 (08) ◽  
pp. 234-242 ◽  
Author(s):  
Peter Walsh

IntroductionFactor XI is a plasma glycoprotein (concentration ∼30 nM) that was first identified by Rosenthal et al1 as a plasma coagulation factor deficiency in patients with abnormal hemostasis, particularly common among Ashkenazi Jews.2,3 In spite of recent advances in our understanding of the structure of factor XI and its gene, the structure-function relationships of the protein, and the molecular genetics of factor XI deficiency, considerable confusion about the physiologic role and clinical relevance of factor XI has arisen from both clinical and biochemical observations. One problem arises from the fact that, until recently, the only known pathway for activation of factor XI involved proteolytic activation by factor XIIa and interactions with coagulation proteins of the contact phase of blood coagulation.4-7 The problem arose from the clinical observation that patients with deficiencies of factor XI are subject to bleeding complications, whereas patients with deficiencies of the contact proteins are not.2,3,8-13 A related unanswered question concerns the lack of correlation in many reported patients between plasma levels of factor XI and the severity of clinical bleeding manifestations.2,3,8,9,13-15 In addition, some patients with severe factor XI deficiency experience significant bleeding complications, whereas others appear to be hemostatically normal. These clinical and biochemical observations have motivated investigations focused on alternative mechanisms for activation of factor XI independent of contact phase protein.19-22 Additional studies have focused on the identification and characterization of platelet factor XI, which is postulated to be an alternative splicing product of the factor XI gene. Platelet factor XI is present in platelet membranes and might substitute for plasma factor XI in hemostasis and account for the absence of bleeding complications in some patients with severe plasma factor XI deficiency.14,16-18,23-26 Studies addressing these two important and related problems are presented and discussed in this chapter.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4449-4449
Author(s):  
Juan Herrada ◽  
Maria Chona Aloba ◽  
Dorothy M Adcock ◽  
Anuradha Gupta ◽  
Luis S. Noble ◽  
...  

Abstract Abstract 4449 Background Factor XI deficiency (known as Rosenthal syndrome or hemophilia C) is an autosomal disorder affecting both sexes which results in a bleeding disorder of variable severity. This condition is very uncommon among the non-Jewish population and consists mostly of sporadic cases, although an occasional familial cluster has been described (Bolton-Maggs et al. J Thromb Haemost 2004 Jun;2(6):918-24). We present two asymptomatic siblings with coagulation Factor XI deficiency. Case Report In February 2004 a healthy 33 year-old non-Jewish white female without personal or family medical history presented with an elevated partial thromboplastin time (PTT) incidentally found during a routine pre-operative evaluation. Her prothrombin time (PT) was normal. Her PTT was 45 seconds (reference interval 23-37 seconds), and normalized with 1:1 mixing studies of patient and normal plasma. Preliminary laboratory evaluation included negative tests for the presence of a Lupus Anticoagulant, a normal serum albumin level, and a normal urinalysis. Additional laboratory testing of coagulation and included FXI and XII activities, measured by means of a one stage APTT-based clotting assay using APTT reagent (Automated APTT, Trinity Biotech, Bray Ireland), congenitally depleted deficient plasma (HRF, Inc, Raleigh NC) using the MDA II Trinity Biotech, Bray Ireland). FXI was 46% (reference range 60-150) and FXII was 42% (reference range 50-150). In March 2004, a repeated the laboratory evaluation showed a FXI of 41% and a FXII of 46%. In April 2006, FXI was 49%, and FXII was 40%. Is to be noted that the patient never had abnormal bleeding episodes despite abdominal and breast surgical procedures. In 2009, her only brother (aged 29 and otherwise healthy) underwent hematological evaluation that showed normal levels of PT, PTT, platelet count, fibrinogen, and factor XII (88% activity). His factor XI was 51% (decreased activity). Conclusion Although modern laboratory methods are able to identify unusual coagulation defects, their clinical significance requires additional investigation. Disclosures: No relevant conflicts of interest to declare.


2003 ◽  
Vol 58 (1) ◽  
pp. 5-8 ◽  
Author(s):  
Débora R. Bertola ◽  
Jorge David A. Carneiro ◽  
Élbio Antônio D'Amico ◽  
Chong A. Kim ◽  
Lilian Maria José Albano ◽  
...  

OBJECTIVE: Noonan syndrome is a multiple congenital anomaly syndrome, and bleeding diathesis is considered part of the clinical findings. The purpose of this study was to determine the frequency of hemostatic abnormalities in a group of Noonan syndrome patients. METHOD: We studied 30 patients with clinical diagnosis of Noonan syndrome regarding their hemostatic status consisting of bleeding time, prothrombin time, activated partial thromboplastin time and thrombin time tests, a platelet count, and a quantitative determination of factor XI. RESULTS: An abnormal laboratory result was observed in 9 patients (30%). Although coagulation-factor deficiencies, especially factor XI deficiency, were the most common hematological findings, we also observed abnormalities of platelet count and function in our screening. CONCLUSIONS: Hemostatic abnormalities are found with some frequency in Noonan syndrome patients (30% in our sample). Therefore, we emphasize the importance of a more extensive hematological investigation in these patients, especially prior to an invasive procedure, which is required with some frequency in this disorder.


Sign in / Sign up

Export Citation Format

Share Document